|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-5-25
|
|
pubmed:abstractText |
In controlled studies of patients with schizophrenia, the atypical antipsychotic quetiapine, 300 mg/day, has been shown to be as effective in the treatment of positive and negative symptoms as haloperidol. However, little is known about the efficacy of quetiapine in patients with psychotic mood disorders. The purpose of this study was to assess the efficacy of quetiapine in the treatment of psychotic mood disorders in comparison with nonaffective psychotic disorders and identify clinical factors associated with quetiapine response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0160-6689
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
185-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10817103-Adult,
pubmed-meshheading:10817103-Affective Disorders, Psychotic,
pubmed-meshheading:10817103-Antipsychotic Agents,
pubmed-meshheading:10817103-Bipolar Disorder,
pubmed-meshheading:10817103-Chronic Disease,
pubmed-meshheading:10817103-Depressive Disorder,
pubmed-meshheading:10817103-Dibenzothiazepines,
pubmed-meshheading:10817103-Female,
pubmed-meshheading:10817103-Hospital Records,
pubmed-meshheading:10817103-Humans,
pubmed-meshheading:10817103-Male,
pubmed-meshheading:10817103-Prognosis,
pubmed-meshheading:10817103-Psychotic Disorders,
pubmed-meshheading:10817103-Retrospective Studies,
pubmed-meshheading:10817103-Schizophrenia,
pubmed-meshheading:10817103-Schizophrenia, Paranoid,
pubmed-meshheading:10817103-Schizophrenic Psychology,
pubmed-meshheading:10817103-Severity of Illness Index,
pubmed-meshheading:10817103-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Clinical predictors of acute response with quetiapine in psychotic mood disorders.
|
|
pubmed:affiliation |
Bipolar and Psychotic Disorders Program, and the Pharmacologic Research and Treatment Center, University of Massachusetts Medical School, Worcester 010655, USA. carlos.zarate@umassmed.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|
